Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET)Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trialsMeta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stentingTroponin T levels in patients with acute coronary syndromes, with or without renal dysfunctionEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trialClopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic eventsFrequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trialPatients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trialProlonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trialImpact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.Smoking, clopidogrel, and mortality in patients with established cardiovascular disease.The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis.Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and AvoidancePlatelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.Variability in platelet responsiveness to clopidogrel among 544 individuals.Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention.Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMEvaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding.Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention.Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial.The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics studyTriple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival
P50
Q28165540-68C83884-1425-4739-86D1-C4E69FE85001Q28174968-D52E8938-73B2-44C9-997D-1BA0060AAC0FQ28191931-3C9D7777-44CF-40A2-8663-83735F9E02A8Q28193293-4492B618-2137-4E0D-A7C5-D866F1611120Q28194232-7671863A-0004-4022-9589-B80CA09707B5Q28195656-DBF07FA6-95C4-424C-9FFA-BF73967BB9A0Q28196878-D054C5A9-0136-42C2-A93F-177326384ADCQ28199508-53A048CB-A267-4777-8EA1-EA8E3A88112DQ28210537-A1399FF1-51EF-434E-B079-7425896B428CQ28218201-EAFCBC0A-6E1E-41D8-8DC7-4985A7920A12Q30421742-9E0B41E3-2CB0-4A00-90AE-E0AC0C853DE9Q33621896-02CDCE8E-910A-475B-9D54-F64A1F62D5E2Q37631913-ABF7EC44-5F66-4C6E-8B3B-DD9C35F13FC9Q38373039-6915BFC8-94C1-4CB1-9BF8-E3C78040DC38Q38485635-594661C1-75EC-4F70-B90B-1ECBFA1297E6Q38493350-341C0E47-6D7A-47D0-AC8C-03644B2F6665Q40454244-33F94459-606A-43FC-BBFC-20DC50CA4099Q43209357-2BF3A0A9-99BA-48AF-86C9-6B3D06A23750Q44571065-78F74D2E-5607-43D5-B7DE-8BC72A5FD39EQ44728786-E5D4A3AE-8245-4002-8A7B-D478F65616DDQ45040769-C65E40B5-3A4A-45FF-B51B-93F36E48B869Q46019314-2062BD68-CC19-45AB-BD63-60B6E7858AA7Q46045986-60F9C486-BDA2-4340-8A60-729C08776782Q46085235-C022E93C-BB58-43A8-91F9-806EDE10E1FDQ46137349-A9ADCB85-9663-474B-BEBC-62E7DF8CB097Q46491524-5D290E9D-9A17-4BB5-AD73-3349ABA0EF1AQ46678652-2533D71B-9AFB-4EEB-9EDA-6B19EA30CDCFQ46708832-2993655C-B82A-41D8-8DCA-4E2959B8A563Q46731360-27FA6464-B4FE-4A8E-BC3B-3A3BD71C38C2Q46974547-33DA0E60-BD30-4541-BBCE-3367D8C2AA36Q51109022-E2F0B8D2-E0A9-4124-9419-41324CF47F90Q53461746-9DB87D33-AF61-4C83-B70B-383E245D84FDQ56944494-55B4283F-90AA-41F8-AE11-EA05ED829AE5
P50
description
American cardiologist
@en
cardiolojiste american
@lfn
cardioloog
@nl
usona kardiologo
@eo
name
Peter B. Berger
@ast
Peter B. Berger
@en
Peter B. Berger
@es
Peter B. Berger
@fr
Peter B. Berger
@nl
type
label
Peter B. Berger
@ast
Peter B. Berger
@en
Peter B. Berger
@es
Peter B. Berger
@fr
Peter B. Berger
@nl
prefLabel
Peter B. Berger
@ast
Peter B. Berger
@en
Peter B. Berger
@es
Peter B. Berger
@fr
Peter B. Berger
@nl
P106
P108
P1280
P21
P31
P569
1956-01-01T00:00:00Z